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ARTICLE
Targeting N-myristoylation for therapy of B-cell
lymphomas
Erwan Beauchamp1,2, Megan C. Yap1,2, Aishwarya Iyer1, Maneka A. Perinpanayagam1,2, Jay M. Gamma3,
Krista M. Vincent4, Manikandan Lakshmanan5, Anandhkumar Raju6,7, Vinay Tergaonkar6,7, Soo Yong Tan6,7,
Soon Thye Lim 8, Wei-Feng Dong4, Lynne M. Postovit 4, Kevin D. Read 9, David W. Gray 9,
Paul G. Wyatt9, John R. Mackey2,4 & Luc G. Berthiaume 1,2✉
Myristoylation, the N-terminal modification of proteins with the fatty acid myristate, is critical
for membrane targeting and cell signaling. Because cancer cells often have increased N-
myristoyltransferase (NMT) expression, NMTs were proposed as anti-cancer targets. To
systematically investigate this, we performed robotic cancer cell line screens and discovered
a marked sensitivity of hematological cancer cell lines, including B-cell lymphomas, to the
potent pan-NMT inhibitor PCLX-001. PCLX-001 treatment impacts the global myristoylation
of lymphoma cell proteins and inhibits early B-cell receptor (BCR) signaling events critical for
survival. In addition to abrogating myristoylation of Src family kinases, PCLX-001 also pro-
motes their degradation and, unexpectedly, that of numerous non-myristoylated BCR
effectors including c-Myc, NFκB and P-ERK, leading to cancer cell death in vitro and in
xenograft models. Because some treated lymphoma patients experience relapse and die,
targeting B-cell lymphomas with a NMT inhibitor potentially provides an additional much
needed treatment option for lymphoma.
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Hematological cancers such as lymphoma account for ~9%of new cancer cases and cancer-related deaths world-wide1–3. Although patients with aggressive non-Hodgkin
lymphomas such as Burkitt lymphoma (BL) and diffuse large B-
cell lymphoma (DLBCL) frequently achieve initial remission with
current therapies, these are toxic and a substantial proportion of
patients experience disease relapse and premature death2,3.
Recent data from the Surveillance, Epidemiology, and End Results
of the National Cancer Institute (NCI) show a 5-year post diag-
nosis survival rate for non-Hodgkin lymphoma and DLBCL,
relative to age-matched controls, of only 70% and 63%, respec-
tively2. The identification of new druggable targets and better-
tolerated treatments for aggressive lymphomas are therefore
much needed.
While B-cell receptor (BCR) signaling is essential for normal B-
cell function, it is often deregulated and provides critical pro-
survival signals for B-cell lymphomagenesis in both BL and
DLBCL4–8. Indeed, the presence of self-antigens and/or muta-
tions in key BCR effectors impact distinct signaling modes of the
BCR. In addition to the ligand activated BCR signaling mode,
these include the chronic active BCR signaling in activated B cell-
like DLBCL and chronic lymphocytic leukemia as well as the
tonic (antigen independent constitutive baseline signaling) BCR
signaling in BLs4–8. Typically, engagement of the BCR leads to the
translocation of this receptor to plasma membrane lipid rafts
containing the myristoylated Src-family kinase (SFK) Lyn9–11.
Myristoylated Lyn phosphorylates select tyrosine residues in the
immune-receptor tyrosine-based motif (ITAM) of the BCR
associated CD79A-CD79B heterodimer12,13 resulting in the
recruitment of spleen tyrosine kinase (SYK). Human germinal
center-associated (HGAL) protein is another myristoylated pro-
tein localized to lipid rafts and is phosphorylated upon BCR
activation14,15. Phosphorylated HGAL enhances BCR signaling
by augmenting the activation and recruitment of SYK to phos-
phorylated ITAMs, triggering the tyrosine phosphorylation of the
Tec family member Bruton’s tyrosine kinase (BTK)16, phospho-
lipase Cϒ, and protein kinase Cβ13. Activated phospholipase Cϒ
activity produces diacylglycerol and inositol-trisphosphate (IP3),
which activate PKCs and mobilize calcium ions from endo-
plasmic reticulum stores respectively. These chemical mediators,
in turn, activate various signaling pathways17. All these early
signaling events promote cell survival and proliferation through
activation of transcription via the NFκB, PI3K, extracellular signal
regulated kinase (ERK) mitogen-activated protein kinase, CREB,
and NF-AT pathways4–6,18. The importance of BCR signaling in
lymphomagenesis has prompted the development of numerous
pharmacological agents, which target effector proteins down-
stream of the BCR including various SFKs (dasatinib), BTK
(ibrutinib), and PI3Kδ (CAL-101)4,5,19,20.
In humans, protein myristoylation is mediated by two ubi-
quitously expressed N-myristoyl-transferases, NMT1, and NMT2,
which add a 14 carbon fatty acid myristate onto numerous
proteins21,22. Myristoylation plays a fundamental role in cell
signaling and allows for the dynamic interactions of proteins with
cell membranes23,24. Myristoylation occurs at the N-terminal
glycine residue of proteins either co-translationally after the
removal of the initiator methionine or post-translationally after
caspase-cleavage during apoptosis23. Up to 600 proteoforms25 in
humans are myristoylated and the proper membrane targeting
and functions of these proteins require myristoylation23,24,26–28.
SFKs, Abl, Gα subunits, Arf GTPases, caspase truncated (ct-) Bid,
and ct-PAK2 are examples of myristoylated proteins that criti-
cally regulate cell growth and apoptosis23,29–35. Recently, NMTs
were also shown to be responsible for myristoylation of N-
terminally located lysine residues of Arf6 GTPase, thereby adding
to their roles in cell signaling36,37. Because NMTs are essential for
the viability of parasites, small molecule inhibitors such as
DDD85646 were developed as a T. brucei NMT inhibitor to treat
African sleeping sickness38. DDD85646 was also synthesized and
validated independently as a bona fide inhibitor of human NMTs
under the name IMP-36639. Because NMT expression levels and
activity are increased in some cancers40–45, NMTs have been
proposed to be anticancer targets43. However, the effect of NMT
inhibitors in cancer has not been systematically investigated.
Herein, we tested the sensitivity of 300 cancer cell lines
encompassing all major cancer types to NMT inhibition by
PCLX-001 in three independent screens. PCLX-001 is an orally
bioavailable derivative of the NMT inhibitor DDD85646, and is
more selective and potent towards human NMTs (Supplementary
Table S1)38. We demonstrate that PCLX-001 inhibits the viability
and growth of hematological cancer cells in vitro more effectively
than the inhibition of viability and growth of other cancer cell
types or select normal cells. PCLX-001 disrupts early BCR-
mediated survival signaling in several B-cell lymphoma cell lines
and promotes the degradation of numerous myristoylated and
non-myristoylated BCR effectors, triggering apoptosis. More
importantly, PCLX-001 produces dose-dependent tumor regres-
sion and complete tumor regressions in two of three lymphoma
murine xenograft models establishing an initial proof-of-concept
for NMT inhibitors as cancer therapeutics and supporting its
ongoing preclinical development.
Results
PCLX-001 selectively kills blood cancer cells in vitro. To
investigate the therapeutic potential of NMT inhibition in cancer,
we performed three independent robotic screens to measure the
percentage growth inhibition (GI) of PCLX-001 in a variety of
cancer cell lines. Using 68 cell lines on the Horizon (St. Louis,
MO) platform, we show PCLX-001 inhibits the growth of a
variety of cell lines (Fig. 1a). GI is significantly higher
(P < 0.0001) however, in hematological (blood) cancer cells
including lymphomas, leukemia, and myelomas than in other
cancer cell line types (Fig. 1b). These results were recapitulated
using a 101 cell line OncolinesTM (Oss, Netherlands) screen
(Fig. 1c, d, P= 0.0001, Supplementary Fig. 1), and in a third
screen (Chempartner, Shanghai, China) whereby 131 cancer cell
lines were exposed to PCLX-001 for 3 and 6 days (Supplementary
Fig. 2). The median IC50 following 3 days of PCLX-001 treatment
is significantly lower in hematological cancer cell lines (0.166 μM)
in comparison to cell lines originating from solid tumors (10 μM,
the highest dose tested; P= 0.0038) including breast cancer, non-
small cell lung cancer, and small cell lung cancer (Supplementary
Fig S2A, B). By day 6 however, PCLX-001 effectively kills nearly
all types of cancer cell lines tested (Supplementary Fig S2C, D).
To confirm the data obtained using screens, we tested the
effects of PCLX-001 treatment on several common B-cell
lymphoma cell lines including the BL cell lines BL2, Ramos,
and BJAB, the DLBCL cell lines DOHH2, WSU-DLCL2, and SU-
DHL-10, and the immortalized B-cells IM9 and VDS46 as
controls. We performed three types of assays on these cells: (1)
CellTiter Blue assay, whose readouts are dependent on both
proliferation (number of total cells) and viability (percentage of
viable cells) to evaluate the total number of viable cells, (2)
Calcein assay, whose readout is independent of proliferation rate
as it only measures the percentage of viable cells and, (3) a cell
proliferation assay to simply count the total number of cells over
time, independently of their viability. Incubation of malignant cell
lines with PCLX-001 kills these cells in a time and concentration
dependent manner in all three assays. Furthermore, PCLX-001
treatment kills malignant cell lines at significantly lower
concentrations than that needed to kill benign IM9 and VDS
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B-cells as measured by both CellTiter Blue (4 to 111 fold less
PCLX-001 needed; Fig. 1e, f) and Calcein (2 to 40 fold less PCLX-
001 needed; Supplementary Fig. 3) assays. PCLX-001 is also better
at inhibiting the proliferation and viability of the six malignant
B-lymphoma cell lines in comparison to benign IM9 and VDS B-
cells (Fig. 1e–h, Supplementary Figs. S3 and S4). To illustrate
this, we show the treatment of malignant BL2 cells with 0.05 and
0.1 μM PCLX-001 completely inhibits their proliferation over
time with little effect on benign IM9 cells at these concentrations
(Fig. 1g, h). Importantly, 96 h PCLX-001 treatment of freshly
isolated human lymphocytes and peripheral blood mononuclear
cells (PBMCs) only marginally affects lymphocyte survival,
whereas 0.1 μM PCLX-001 causes an ∼50% decrease in PBMC
survival (Supplementary Fig. 5). The surviving PBMCs however,
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endure PCLX-001 treatment up to a concentration of 10 μM, a
dose ∼100× greater than the IC50 (∼0.050–0.100 µM) for most
hematological cancer cell lines in vitro. A similar trend is
observed in primary human umbilical vein endothelial cells
(HUVECs; Supplementary Fig. 5B). Taken together, these data
show that PCLX-001 treatment selectively inhibits the prolifera-
tion and viability of a variety of cancer cell lines in a time and
concentration dependent manner, and is particularly efficient at
killing malignant hematologic cancer cells in vitro.
Myristoylation inhibition induces lymphoma cell apoptosis. To
verify that PCLX-001 acts on target, we used click chemistry as
described47 to visualize the inhibition of endogenous protein
myristoylation in malignant BL2 lymphoma cells and benign IM9
B-cells (Fig. 2a, b). PCLX-001 inhibits total protein myristoylation
in a concentration dependent manner in both cell lines. However,
only ∼0.1 μM of PCLX-001 is required to decrease BL2 myr-
istoylation compared to five times this amount in IM9 cells
(Fig. 2a, b). This suggests that protein myristoylation processes in
malignant BL2 cells may somehow be more sensitive to PCLX-
001 inhibition. Although PCLX-001 (Supplementary Table S1)38
is a closely related analog of DDD85646/IMP-366 and part of
a series of recently validated NMT inhibitors38,39, we further
evaluated its effect on palmitoylation and phosphorylation.
PCLX-001 does not inhibit the palmitoylation of an EGFP-N-Ras
construct expressed in COS-7 cells (Supplementary Fig. 6A), nor
does it significantly inhibit any of the 468 human kinases of the
pre-configured scanMAX KINOMEscanTM (Eurofins DiscoverX,
San Diego, USA) at concentrations up to 10 µM (Supplementary
Fig. 6B). Of note, only three possible positive hits were found at
100 µM PCLX-001, a concentration ∼4000× greater than the
EC50 of PCLX-001 for BL2 cells. Thus, the time and con-
centration dependent effects of PCLX-001 on cellular function
and viability appear NMT-specific.
We next verified PCLX-001 inhibition of NMT function by
monitoring the myristoylation and localization of Src protein
tyrosine kinase, a known myristoylated protein, using truncated
Src-EGFP48 constructs expressed in COS-7 cells by click
chemistry47 and fluorescence microscopy. PCLX-001 inhibits
the myristoylation of both the WT-Src-EGFP construct and
endogenous Src in a concentration dependent manner in COS-7
and IM9 cells, respectively (Fig. 2c, d). Notably, myristoylation
inhibition relocalizes WT-Src-EGFP from the plasma and
endosomal membranes to the cytoplasm in COS-7 cells,
producing a distribution pattern comparable to that of the non-
myristoylatable Gly2Ala-Src-EGFP mutant construct48 (Fig. 2e).
Inhibiting endogenous Src myristoylation also produces an
unexpected time-dependent reduction in Src protein levels in
BL2 and IM9 cells treated with PCLX-001 for up to 5 days
(Fig. 2f) that is accelerated in malignant BL2 cells in comparison
to IM9 controls (P= 0.0174; Supplementary Fig. S7). Further-
more, PCLX-001 treatment selectively induces apoptosis in the
BL cell lines BL2 and Ramos, but not immortalized IM9 B-cells as
measured by PARP-1 and caspase-3 cleavage (Fig. 2g), consistent
with benign, immortalized B-cells exhibiting a higher threshold
for PCLX-001 toxicity (Fig. 1e, f, Supplementary Fig. 3).
Altogether, these data suggest that PCLX-001 preferentially
abrogates myristoylation in malignant lymphoma cells in
comparison to normal immortalized B cells leading to selective
cell death.
PCLX-001 reduces SFK levels and BCR downstream signaling.
BCR signaling provides key survival signals in B-cell lymphomas,
and SFKs (especially Lyn) play a critical role in initiating BCR
signaling in both normal B-cells and lymphomas5,6,11,49,50. Since
PCLX-001 treatment preferentially reduces endogenous Src protein
levels in malignant BL2 cells in comparison to benign IM9 controls
(Fig. 2f), we sought to determine if a similar effect could be
observed on other SFKs in various lymphoma cell lines. We found
that PCLX-001 treated BL2, Ramos, BJAB, DOHH2, WSU-DLCL2,
and SU-DHL-10 lymphoma cells all exhibit a more pronounced
dose and time dependent decrease in Src and Lyn SFK protein
levels in comparison to benign IM9 and VDS controls (Fig. 3a). To
investigate whether the proteasome degradation mechanism was
involved, after addition of PCLX-001 to BL2 cells for 24 or 48 h, we
treated BL2 cells with the proteasome inhibitor MG132 or not for
6 h prior to harvesting and lysing the cells, and, measuring residual
protein levels of not only Src and Lyn SFKs, but also hematopoietic
cell kinase (Hck) and lymphocyte specific kinase (Lck) SFKs, both
of which are also linked to lymphoma progression50. PCLX-001
treatment reduces Hck and Lck protein levels to a lesser degree
than Src and Lyn (Fig. 3b). However, the addition of MG132 to
PCLX-001 treated cells results in partial or complete restoration of
the 4 SFK proteins in comparison to controls, especially at the 24h
time point (Fig. 3b). This indicates that the degradation of non-
myristoylated-SFKs can be attributed in part to the ubiquitin-
proteasome system. The efficacy of the proteasome inhibition by
MG132 was confirmed by monitoring Mcl-1 levels, a protein
actively degraded by the proteasome51 (Fig. 3b).
Because antigen independent basal BCR signaling is often
elevated in lymphoma cells6,49, we assessed the impact of PCLX-
001 treatment on ligand independent BCR signaling by monitor-
ing endogenous tyrosine phosphorylation levels in the above cell
lines using an anti-phospho-tyrosine (P-Tyr) antibody (PY99).
24 h treatments with PCLX-001 decreases antigen independent
global phospho-tyrosine levels in all cell lines tested in a
concentration dependent manner (Supplementary Fig. 8A). In
addition, 1 μM PCLX-001 abrogates nearly all ligand dependent
BCR mediated phospho-tyrosine and pan-phospho-SFK levels in
BL2 cells after BCR ligation with anti-IgM (Fig. 3b). While
Fig. 1 PCLX-001 selectively kills hematological cancer cell lines in comparison to cancer cell lines of other origins. Percentage of maximum growth
inhibition of various cell lines following 96 h treatment with 1.2 μM PCLX-001 as determined using a Horizon cell line screen (a, b), or following 72 h
treatment with 1 μM of PCLX-001 using a OncolinesTM cell line screen (c, d). Cell lines are arranged according to tumor cell type. Cross-hatched zone
represents cytotoxic effect. Hematological cancer cell lines are depicted in gray while all other types of cancer cell lines are depicted in white.
Corresponding violin graphs compare the average PCLX-001-mediated growth inhibition on hematological cancer cell lines to cancer cell lines of other
origins combined as calculated from the Horizon (b) and OncolinesTM (d) cell screens (Unpaired t test, two-tailed P < 0.0001). Quartiles are separated by
dotted lines. Error bars represent standard deviation within each group. Normalized cell viability curves of immortalized lymphocyte (IM9, VDS), BL (BL2,
Ramos, BJAB), and DLBCL (DOHH2, WSU-DLCL2, SU-DHL-10) cell lines treated with 0.001–5 μM of PCLX-001 for 96 h as determined by CellTiter Blue
Viability Assay (e). Corresponding histograms of absolute IC50 (and SD) values calculated from a log(inhibitor) vs response (three parameters) equation
cell viability curves plotted in e (f). ***Indicates a significant difference (P≤ 0.001) in IC50 between IM9 cells and all other cell lines tested (Ordinary one-
way Anova, Tukey’s multiple comparisons test, P < 0.0001). Normalized proliferation of IM9 (g) and BL2 (h) cells reated with 0–5 μM of PCLX-001 for
96 h as determined by cell count. Values are mean ± s.e.m. of three independent experiments. Source data are provided as a Source Data file.
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proteasome inhibition results in the stabilization of SFKs as
suggested by their increased protein levels, it does not reverse the
impact of PCLX-001 on ligand independent tyrosine phosphor-
ylation, or overall SFK phosphorylation in BL2 cells (Fig. 3b)
supporting the established notion that non-myristoylated SFKs
are no longer functional because of their mislocalization and their
inability to phosphorylate their substrates. Altogether, these
results indicate that the myristoylation of SFKs is essential for
both their activity and stability, and is required for downstream
BCR signaling in lymphoma cells.
PCLX-001 potently inhibits BCR survival signaling compo-
nents. Since PCLX-001 impacts SFK protein levels and ligand
dependent BCR mediated tyrosine phosphorylation, we next
evaluated its effects on other BCR mediated signaling
intermediates using two clinically approved BCR signaling inhi-
bitors: dasatinib (a broad spectrum tyrosine kinase inhibitor) and
ibrutinib (a BTK inhibitor) as controls52. Because BL2 cells were
found to be most responsive to anti-human IgM BCR stimulation
(Supplementary Fig. 8B), these cells were chosen as a model for
studying PCLX-001-mediated effects on activated BCR signaling.
BL2 cells treated with 0.1 or 1.0 µM PCLX-001 exhibit con-
centration dependent partial (at 24 h, Supplementary Fig. 8B) and
near complete abrogation (at 48 h) of anti-IgM stimulated BCR
mediated tyrosine phosphorylation (Fig. 4a, quantification in
Supplementary Fig. 9). The overall reduction in tyrosine phos-
phorylation is more pronounced in BL2 cells treated with PCLX-
001 than those treated with dasatinib or ibrutinib at the same
concentrations. PCLX-001 treatment also reduces or abolishes
levels of total Lyn, activated-phosphorylated-Lyn (Y396), as well
as that of total BTK and activated-phosphorylated-BTK (Y223) in
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Fig. 2 PCLX-001 selectively inhibits myristoylation in vitro and induces apoptosis in lymphoma cell lines. Click chemistry was used on alkyne-myristate
labeled cell lysates to determine overall protein myristoylation levels in: BL2 cells (a) and IM9 cells (b) treated for 1 h with 0.01–1.0 µM PCLX-001,
myristoylation levels of a WT-Src-EGFP construct expressed in COS-7 cells (c) and, myristoylation of immunoprecipitated endogenous pp60-Src in IM9
cells following 1 h treatment with 1.0–10 µM of PCLX-001 (d). Fluorescence micrographs of COS-7 cells transfected with a WT-Src-EGFP (left), non-
myristoylatable G2A-Src-EGFP mutant (center), and a WT-Src-EGFP construct treated with 10 μM PCLX-001 for 24 h (right) (e). Scale bars are equal to
10 μm. Endogenous Src protein levels in IM9 and BL2 cells treated with 1 μM PCLX-001 for 0–5 days measured by Western blotting (f). Western blotting of
cleaved PARP-1 and cleaved caspase-3 in IM9, BL2, and Ramos cell lysates following 72 h incubation with 0–1.0 µM PCLX-001 (composite gels) (g). All
data shown are representative of at least three independent experiments. GAPDH serves as loading control. Source data are provided as a Source Data file.
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BL2 cells (Fig. 4a). These findings were confirmed in several other
lymphoma cell lines (Supplementary Fig. 10) and for several other
SFKs including Src, Lck, Hck, and Fyn, as well as for activated-
pan-phospho-SFKs in BL2 cells (Fig. 4a, Supplementary Fig. 11).
Dasatinib and ibrutinib selectively inhibited their respective tar-
gets as measured using anti-P-Lyn, anti-P-SFKs, and anti-P-BTK
antibodies (Fig. 4a).
PCLX-001 treatment also mediates the reduction of other
myristoylated protein levels including the BCR signaling
enhancer protein HGAL and Arf1 GTPases while dasatinib and
ibrutinib have no effect on the levels of either of these proteins
(Fig. 4b, c). Of note, the loss of HGAL protein was much faster
than that of SFKs and Arf1 GTPase and the loss of HGAL protein
levels is associated with a reduction in the phosphorylated and
active form of SYK as expected14,15 (Fig. 4b). Since the levels of
both myristoylated HGAL and myristoylated small GTPase Arf1
are also diminished upon PCLX-001 treatment, the ability of
PCLX-001 to promote the degradation of myristoylated proteins
is therefore not restricted to myristoylated SFKs (Fig. 4).
BCR signaling ultimately converges on transcription factors
involved in B-cell proliferation and survival including phospho-
ERK (P-ERK), NFκB, c-Myc, and CREB4,5. Thus, we evaluated
the effects of PCLX-001, dasatinib, and ibrutinib on these
effectors at 0.1 and 1.0 μM for 48 h on BL2 cells. Consistent with
an impairment in BCR signaling, PCLX-001 reduces the levels of
P-ERK, NFκB, c-Myc, and CREB in a concentration dependent
manner with statistically significant decreases (P < 0.05) detected
in phospho-ERK and NFκB levels (Fig. 4c, quantification in
Supplementary Fig. 9). Again, these effects tend to be more
marked in PCLX-001 treated cells than those treated with either
dasatinib or ibrutinib. These findings, including decreased levels
of Src, Lyn, pan-P-SFK, ERK, and P-ERK, are also observed in
several other malignant lymphoma cell lines (Supplementary
Fig. 10). We also show PCLX-001 treatment increased the levels
of the ER stress pro-apoptotic marker Bip more than dasatinib
and ibrutinib treatments leading to an overall increase apoptosis
as measured by caspase-cleaved PARP1 (Fig. 4c). Therefore, the
ability of PCLX-001 to promote the degradation of proteins is not
restricted to its effects on myristoylated proteins such as SFKs,
HGAL, and Arf1 but also includes effects on non-myristoylated
proteins such as phospho-ERK and NFκB signaling downstream
the BCR.
Early events in BCR signaling also culminate in the activation
of phospholipase Cϒ and calcium mobilization in the cytosol. We
demonstrate that PCLX-001 (1 μM) treatment of BL2 cells for 48
h potently inhibits anti-IgM BCR-induced calcium mobilization
from intracellular stores using a fluorescent ratiometric Fura-2
Ca++-chelator assay53 (Supplementary Fig. 12). In addition to
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Fig. 3 PCLX-001 treatment results in SFK instability and degradation by the proteasome in lymphoma cell lines. Western blot for total Src and Lyn
proteins in immortalized lymphocyte (IM9, VDS), BL (BL2, Ramos, BJAB), and DLBCL (DOHH2, WSU-DLCL2, SU-DHL-10) cell line lysates following
24–48 h of treatment with 0.1 µM or 1.0 μM PCLX-001 (a). After BCR ligation with anti-IgM, western blot for total Src, Lyn, Hck, Lck, Mcl-1, total phospho-
tyrosine (PY99) and pan phosphorylated-SFK (P-SFK) protein levels in BL2 treated for 24–48 h with 1 µM PCLX-001 in the presence or absence of 10 µM of
the proteasome inhibitor MG132 for the last 6 h (b). GAPDH serves as a loading control. All western blots shown are representative of three independent
experiments. Source data are provided as a Source Data file.
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drastically reducing the intensity of the calcium release peak, and
similarly to dasatinib treatment, PCLX-001 delayed the calcium
release process. Overall, PCLX-001 inhibited calcium mobiliza-
tion more than either dasatinib and ibrutinib used at the same
concentration. Of note, extended treatment of BL2 cells with
PCLX-001 for 48 h interfered with calcium homeostasis and lead
to increased basal levels of cytosolic calcium (Supplementary
Fig. 12), perhaps contributing to ER calcium depletion and
apoptosis. In all, our data indicate that PCLX-001 treatment
effectively impairs BCR-mediated pro-survival signaling and
induces apoptosis in lymphoma cells (Fig. 5).
Because PCLX-001, dasatinib and ibrutinib varied in potency
and differentially affected downstream BCR signaling, we next
compared the effects of these drugs on the overall viability of the
lymphoma cell lines tested above. Dasatinib and ibrutinib
treatments have minimal effect on BL2 (solid lines) and IM9
(dotted lines) cells following 48 and 96 h of treatment, whereas
PCLX-001 kills malignant BL2 cells (solid line) at a substantially
lower concentration than that required to kill benign, IM9
controls (dotted line) (Fig. 6a, b). Similar trends in cell viability
are observed across all other cell lines with exception of SU-DHL-
10, which was equally sensitive to both PCLX-001 and dasatinib
(Fig. 6c, d). Of note, these treatments resulted in less than 25%
cell death for PCLX-001 at 48 h and <5% for dasatinib and
ibrutinib at either concentrations used (Fig. 6a and c).
Importantly, the combination treatment of either dasatinib or
ibrutinib at concentrations of 0.1 and 1.0 μM to PCLX-001 at
0.01, 0.1, and 1.0 μM does not further decrease viability
suggesting that PCLX-001 effects are mediated upstream of
dasatinib and ibrutinib targets (Supplementary Fig. 13). Alto-
gether, PCLX-001 has the broadest spectrum of potency against
malignant lymphoma cell lines at both 48 and 96 h in comparison
to dasatinib and ibrutinib, and is better at sparing benign,
immortalized IM9 and VDS B-cell controls, demonstrating higher
selectivity and an in vitro therapeutic window superior to that of
two clinically approved drugs.
NMT expression is altered in hematologic cancer cells. While
we still do not know why hematological cancer cells are more
vulnerable to PCLX-001 than other cancer cell types, we think
this might be related to alterations in NMT1 or NMT2 expression
in hematological cancer cells. To substantiate this possibility, we
performed in silico analyses of gene expression data from the
Cancer Cell Line Encyclopedia54. We first find that the NMT1
number of transcripts is about eight times (23) the number of
NMT2 transcripts in all cell lines on average, and second, that
there is a heterogenous but significant reduction of NMT2
expression in numerous hematological cancer cell lines in com-
parison to other types of cancer cell lines (Supplementary
Fig. 15A, B). Expression of NMT1 is relatively constant across the
1269 cell lines investigated with a slight but significant decrease in
expression in breast and leukemia cancer cell lines while NMT2
expression varies significantly amongst various cancers and also
within a given cancer type (Supplementary Fig. 15C, D). The data
also illustrate that while the expression of NMT2 is higher in
cancer cell lines of CNS, kidney and fibroblast origins there is a
selective and significant reduction of NMT2 expression in
hematological cancers such as leukemia, lymphoma and myeloma
(Supplementary Fig. 15D). Interestingly, the low NMT2 expres-
sion levels seen in lymphomas, leukemia and other cell lines were
not compensated by an increase in NMT1 expression (Supple-
mentary Fig. 15E). Altogether, we find a reduction in NMT2
expression in hematological cancer cell lines, which may account
for their increased sensitivity to PCLX-001.
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Fig. 4 PCLX-001 treatment attenuates BCR downstream signaling events in BL2 lymphoma cells.Western blot of BL2 cells treated for 48 h with 0.1 µM
or 1.0 μM of dasatinib, ibrutinib or PCLX-001 to detect total tyrosine phosphorylation (P-Tyr), Lyn, Lyn phosphorylated on tyrosine 396 or 507, BTK, and
BTK phosphorylated on tyrosines 223 or 551 (a), HGAL, SYK, phosphorylated SYK (P-SYK) (b) or ERK, phosphorylated ERK (P-ERK), NFκB, c-Myc, CREB,
Arf-1, BIP, and PARP-1 (c). Western blots are representative of at least three independent experiments. GAPDH serves as a loading control. BL2 cells were
activated with 25 μg/ml F(ab’)2 anti-human IgM for 2 min and processed for western blotting. All western blots shown are representative of three
independent experiments. Source data are provided as a Source Data file.
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PCLX-001 treatment has potent anti-tumor activity in vivo.
Based on lymphoma cell sensitivity to NMT inhibition in vitro,
we investigated whether PCLX-001 could mitigate tumor pro-
gression in vivo in two murine lymphoma cell line-derived sub-
cutaneous tumor xenograft models and used doxorubicin as a
clinically approved drug reference. In mice bearing DOHH2
tumors, PCLX-001 demonstrates a significant tumoricidal effect
when given daily at 20 mg/kg or every other day at 50 mg/kg (P <
0.001) (Fig. 7a). At 50 mg/kg daily, PCLX-001 reduces tumor size
by up to 70% by day 7 (average tumor size at day 7= 44.0 ± 8.1
mm3), but this was accompanied by significant weight loss,
necessitating a 5-day treatment interruption (Supplementary
b
a
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Fig. 14A). Upon resuming treatment, a mean tumor growth
inhibition (TGI) of 95% is observed by day 16. By comparison,
doxorubicin treatment causes a 57% TGI and reduced body
weight by up to 8% (Supplementary Fig. 14A). Importantly,
treatment with PCLX-001 does not increase mortality at any dose
(Supplementary Fig. 14B).
In mice bearing BL2 xenografts, PCLX-001 shows partial TGI
at doses of 20 mg/kg daily reaching 42.5% tumor regression by
day 9 (P= 0.016) (Fig. 7b). Furthermore, 50 or 60 mg/kg daily
doses of PCLX-001 cause 100% tumor regression in nine of nine
and seven of seven surviving mice, respectively, when adminis-
tered for 13 days. Kaplan–Meier survival analysis of this xenograft
model also shows that PCLX-001 doses between 20 and 50 mg/
kg/day prolongs the survival of BL2 tumor bearing mice in
comparison to untreated, vehicle controls (Supplementary
Fig. 14D, E). Doxorubicin by contrast has no effect on BL2
tumor growth (Fig. 7b), and treatment was terminated at day 11
due to the adverse effects (Supplementary Fig. 14C). At the
conclusion of treatment, we measured NMT activity21 in BL2
tumor lysates and find it to be reduced in a PCLX-001
concentration-dependent manner (P= 0.03; Fig. 7c) showing
that PCLX-001 acts on target in vivo.
Because cell line derived xenografts lack the complexity of
human tumors, we dissected and propagated a DLBCL lym-
phoma derived from patient DLBCL3 whose cancer was
refractory to multiple lines of chemotherapy including CHOP,
RICE, intrathecal methotrexate/cytarabine, and DHAP (Supple-
mentary Table 2) to establish a patient-derived xenograft model
in NODscid mice. Treatments were assessed in groups of 8 mice
each. A 20 mg/kg subcutaneous daily dose of PCLX-001
treatment for 21 days results in 66% TGI (P < 0.001; Fig. 7d).
This dose was then increased to 50 mg/kg daily in another set of
mice for two 9-day periods separated by a 3-day treatment
interruption to allow the mice to recover from ∼15% loss of body
weight (Supplementary Fig. 14F). Following this higher dose
regimen, PCLX-001 administration results in complete tumor
regression in 6 of 7 surviving mice at day 13 (Fig. 7d) with one
mouse with no detectable tumors dying at day 11 (Supplementary
Fig. 14G). Surgically removed tumors from vehicle-control and
PCLX-001 treated mice confirm a concentration-dependent
reduction in overall tumor size following 21 days of PCLX-001
treatment (Fig. 7e) concomitant with increased in apoptosis
(increased cleaved caspase-3; Fig. 7f) and reduction in cell
proliferation (as determined by Ki-67 analysis; Fig. 7g). Thus,
PCLX-001 treatment induces apoptosis and cell-cycle arrest in a
patient-derived lymphoma tumor in vivo in a dose-specific
manner. The effect of doxorubicin treatment could not be
assessed due to severe drug toxicity and death in the majority of
tumor bearing mice within the first 7 days of the experiment.
Mice tolerate PCLX-001 at efficacious dose levels. Mice toler-
ated PCLX-001 at efficacious doses without specific end-organ
toxicity. All mice treated with PCLX-001 survived the first
xenograft study (Fig. 7a), while some mice treated with PCLX-001
at higher dose levels died in the other two studies (Fig. 7b, d).
Neither the clinical pathology nor anatomic pathology evalua-
tions identified the cause of death. Findings suggesting toxicity
were seen in two studies. Of three mice bearing BL2 xenografts
and given PCLX-001 at 50 mg/kg daily with a short treatment
holiday, all had lower-than-normal neutrophil and lymphocyte
counts at the end of the dosing period, and one also had lower-
than-normal monocyte and platelet counts. In mice bearing
DLBCL lymphoma cell xenografts and given PCLX-001 at 20, 50,
or 60 mg/kg daily, signs of ill health (e.g., rough and scruffy coats;
piloerection) were noted in most mice at all dose levels, and
dehydration and weight loss were noted at 50 and 60 mg/kg daily
(Supplementary Tables 3–8).
Dose ranging toxicology studies in rat and dog have been
performed and reported55, and formal GLP toxicology studies in
these species are nearing completion in preparation for regulatory
review for human clinical trials.
Altogether, our results demonstrate that PCLX-001 treatment
inhibits the growth of lymphomas in vivo, including the complete
regression of disease refractory to other clinically approved
treatments and thus establishes a proof-of-concept for the use of a
bona fide NMT inhibitor such as PCLX-001 in cancer.
Discussion
Herein, we report the discovery that hematological cancer cells,
particularly B-cell lymphomas, are highly sensitive to myr-
istoylation inhibition by the novel pan-NMT inhibitor PCLX-001.
While the concept of killing cancer cells with a NMT inhibitor
has been proposed and tested on small scales39,43,56–59, to our
knowledge this work represents the original investigation of the
breadth of efficacy of this approach across hundreds of cancer cell
lines. We demonstrate that cancer cells can be selectively killed by
a NMT inhibitor at concentrations lower than that required to kill
and inhibit the proliferation of immortalized and normal cells
(Fig. 1e–h, Supplementary Figs. 3 and 4). In the absence of
additional cytotoxicity assays in more normal cell types, based on
the benefit/risk for this therapeutic indication, it is acceptable and
not unusual that some normal tissues (e.g., blood cells including
PBMCs) are effected at efficacious doses. Our data indicate a large
enough therapeutic window critical to support the development
of PCLX-001 as a potential cancer treatment. In addition to
inhibiting the myristoylation of a large number of myristoylated
proteins in B lymphoma cells (Fig. 2a, b), we demonstrate that
PCLX-001 is especially efficient at inhibiting BCR signaling,
which is the main lymphoma pro-survival pathway in these
cells4–8. In addition, the PCLX-001 BCR signaling inhibition is
superior to that of clinically approved SFK inhibitor dasatinib and
the BTK inhibitor ibrutinib. This may explain in part why PCLX-
001 also has the broadest spectrum of potency against malignant
lymphoma cell lines in vitro. We also show PCLX-001 inhibits the
myristoylation of SFKs, HGAL, and Arf1 and increases their
degradation rates, but also unexpectedly promotes the
Fig. 5 Model depicting proposed PCLX-001 mechanism of action in B cell lymphoma. a Upon BCR activation, first the myristoylated SFK Lyn is recruited
to the lipid raft domains of the plasma membrane containing the BCR, dephosphorylated Lyn at Y507 leads to its activation and autophosphorylation at
Y396. This leads to the phosphorylation and activation of BTK at Y551 and Y223. Second, myristoylated HGAL is also recruited to the plasma membrane
and phosphorylated thereby enhancing BCR signaling by stimulating SYK, BTK and the release of Ca++ ions from the endoplasmic reticulum via the
inositol-3-phosphate ion channel receptor (IP3R). Altogether these early signaling events lead to transcription activation by c-Myc, P-ERK, NFκB, and CREB.
b The NMT inhibitor PCLX-001 prevents the myristoylation of Lyn-SFK (as well as other SFKs not shown in this model), HGAL and Arf1 thereby impeding
the proper membrane targeting and function of these proteins. PCLX-001 treatment impedes calcium homeostasis by reducing the BCR mediated Ca++
release from the ER and increasing basal Ca++ levels in cells in addition to promote the degradation of both myristoylated (Lyn, HGAL, Arf1) and,
surprisingly, non-myristoylated proteins (NFκB, P-ERK, c-Myc and CREB), some via the ubiquitin-proteasome pathway thereby further abrogating
downstream BCR signaling and increasing ER stress leading to apoptosis and cell death.
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degradation of non-myristoylated pro-survival BCR mediators
including P-ERK, NFκB, c-Myc, CREB, and perhaps even BTK
(Fig. 4a). PCLX-001 treated cells still remained at least 75% viable
at concentrations that are becoming cytotoxic. Whether the lower
downstream signaling protein levels correspond to a reduction in
gene transcription or increased protein degradation in dying cells
is not known. Furthermore, PCLX-001 also reduces BCR-
mediated calcium mobilization causing apoptosis selectively in
B cell lymphoma cells (Fig. 5). The mechanism linking the loss of
myristoylation to alterations in calcium homeostasis and inhibi-
tion of BCR mediated calcium release is not known.
Increased ER stress is a pro-apoptotic phenomenon previously
shown in cells treated with another NMT inhibitor59. We pos-
tulate the inhibition of myristoylation of the Arf1 GTPase, whe-
ther at its N-terminal glycine residue or nearby lysine residue36,37,
interferes with its membrane targeting and impairs vesicle traf-
ficking thereby detrimentally affecting chronic/tonic or antigen
dependent BCR signaling. Loss of proper Arf1 functionality at the
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Fig. 6 PCLX-001 selectively kills hematological cancer cells relative to benign lymphocytes in comparison to dasatinib and ibrutinib. Cell viability
curves of BL2 (solid lines) and IM9 cells (dotted lines) treated for 48 h (a) or 96 h (b) with 0.001–5 µM dasatinib, ibrutinib, or PCLX-001(2way Anova,
Tukey’s multiple comparisons test, P < 0.0001) . Normalized cell viability of immortalized lymphocyte (IM9, VDS), BL (BL2, Ramos, BJAB), and DLBCL
(DOHH2, WSU-DLCL2, SU-DHL-10) cell lines treated with 0.1 µM or 1.0 μM of dasatinib, ibrutinib or PCLX-001 for 48 h (c) and 96 h (d). Cell viability for
all experiments was measured using Calcein assay and is an average of three independent experiments. (Ordinary one-way Anova, Dunnett’s multiple
comparisons test) Errors bars depict s.e.m. Source data are provided as a Source Data file.
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ER may also explain in part the increase in ER stress marker Bip60
upon PCLX-001 treatment (Fig. 4c).
The loss of lipid raft localized myristoylated Lyn (and other
SFKs) and HGAL proteins in PCLX-001 treated cells further
highlights the importance of these membrane domains in proper
BCR signaling9,10,12–15 (Fig. 5). Furthermore, PCLX-001-
mediated myristoylation inhibition of SFKs not only abrogates
their membrane targeting but also promotes their degradation via
the ubiquitin-proteasome system as MG132 treatments resulted
in near complete recovery of SFK levels (Fig. 3b). While ubi-
quitination and degradation of protein tyrosine kinases by the
Casitas B lineage lymphoma-family of E3 ubiquitin ligases61,62 is
a normal part of the signal attenuation in B cells, an N-terminal
glycine residue has also recently been shown to be a destabilizing
factor for proteins, representing a highly selective novel class of
N-degron63. Indeed, in their report, Timms et al. demonstrate
that unmyristoylated proteins including Lyn, Fyn and Yes,
exposing their N-terminal glycine residue are selectively degraded
by the N-terminal glycine specific Cullin RING Ligase 2 (CRL2)-
ZYG11B/ZER1 N-degrons–ubiquitin–proteasome system63. This
system is highly selective for proteins with a N-terminal glycine
residue since substitutions of glycine for any other amino acid led
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Fig. 7 PCLX-001 treatment reduces tumor volumes and leads to complete tumor regression in B-cell lymphoma xenograft models. Dose–response
curves for murine subcutaneous xenografts derived from cell lines measuring the size of DOHH2 (a) and BL2 (b) tumors as a function of time. Error bars
represent the standard deviation of average tumor volumes (n = 10 per group). Average total NMT specific activity assessed as previously described21 in
BL2 tumor samples from mice treated with PCLX-001, doxorubicin, or vehicle alone at the indicated doses. Tumor extracted from mice treated with
60mg/kg/day have reduced NMT specific activity as compared to vehicle (paired t-test, P = 0.0425). Error bars represent s.e.m. (c). Dose–response
curve for the murine xenograft derived from patient DLBCL3. Datapoints represent average tumor volumes in all surviving animals. Error bars represent the
standard deviation in the average tumor volumes (d). ***Indicates a significant difference in response rate between animals which received 20mg/kg/day
and 50mg/kg/day of PCLX-001 (P < 0.0001, n= 8 per group). Representative tumors from mice with patient-derived DLBCL3 xenografts (e).
Representative IHC staining for cleaved caspase-3 (f) and Ki-67 (g) in the above DLBCL3 patient xenograft tumor samples. Scale bars equal to 100 μm.
Source data are provided as a Source Data file.
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to a substantial stabilization of the resulting proteins63. This
newly described N-degron system63,64 may therefore contribute
to the faster degradation of unmyristoylated proteins seen in
malignant lymphoma cell lines treated with PCLX-001 such as
SFKs, HGAL, and Arf1 (Fig. 4). It might also explain in part why
non-myristoylatable Gly2Ala-Src tyrosine kinase mutant and
Gly2Ala-HGAL were previously shown to be more stable than
their myristoylated counterpart proteins65,66 since the artificial
N-terminal alanine (Ala) residue would prevent the promotion of
degradation by the glycine (Gly) residue specific CRL2-ZYG11B
or CRL2-ZER1 N-degrons. Thus, we propose a model for the
mode of action of PCLX-001 in B-cell lymphoma whereby inhi-
bition of myristoylation of SFKs (or other proteins including
HGAL and Arf1) results not only in a loss of membrane targeting
but also in a loss of their protein levels and thus function, via the
ubiquitin–proteasome system (Fig.3B), thereby dampening the
propagation of BCR signals (Fig. 5). Interestingly, NMT1 was
found to be phosphorylated by Lyn, Fyn, and Lck SFKs and that
phosphorylation of NMT1 was necessary for myristoylation
activity since a non-phosphorylatable Y100F-NMT1 mutant lost
98% of its catalytic activity67. Therefore, the PCLX-001 mediated
loss of SFKs could further reduce NMT1 activity in B lymphoma
cells thereby potentiating the loss of pro-survival signals and
apoptosis.
In addition to the effects depending on myristoylated SFKs,
HGAL, and Arf1 proteins, given that there are hundreds of
known myristoylated proteins, PCLX-001-mediated effects on
lymphoma cell viability likely also occur via the loss of func-
tionality of other myristoylated proteins. Although we still do not
know why hematological cancer cells are more vulnerable to
PCLX-001 than other cancer cell types, we think this is possibly
related to altered expression of either NMT1 or NMT2. Analysis
of CCLE NMT1 or NMT2 expression data (Supplementary
Fig. 15) reveals that in addition to be overexpressed in some
cancers (aka the current dogma), NMT expression levels are
actually lower in other cancers, many of which are of hemato-
logical origin. Altogether, these observations suggest a possible
link between the reduction in the number of NMT enzyme targets
in hematological cancer cells and the sensitivity of these cells to
PCLX-001. Whether altered NMT levels impact on the sensitivity
of hematological cancer cells on their own or possibly work in
combination with variations in the individual myristoylated
proteomes of hematological cancer cells, and, the cell-specific
reliance of these cells on various myristoylated proteins for sur-
vival is not known. While these possibilities are currently under
further investigation in our laboratory, the potential importance
of NMT activity to lymphoma cell survival was confirmed in a
genome-wide Cas9-Crispr screen in which NMT1 ranked
amongst the most critical survival factors in lymphoma cell
lines68. In addition, our cancer cell line screen results suggest
potential for a broader application of PCLX-001 to treatment of
leukemia and myeloma, as well as certain solid tumors such as
breast and lung cancers.
While PCLX-001 is only marginally efficacious at the tolerated
dose of 20 mpk [∼66% tumor reduction (Fig.7)], we show that it
effectively inhibits tumor cell growth in vivo resulting in either
major or complete regression of disease in three human lym-
phoma xenograft models at the 50 mpk efficacious dose, includ-
ing complete response in a lymphoma refractory to CHOP,
Rituximab, and other salvage therapies.
In conclusion, we establish our initial proof-of-concept that a
small molecule NMT inhibitor, PCLX-001, potently and selec-
tively inhibits the growth of a wide spectrum of cultured cancer
cells in vitro, with particularly pronounced effects in cells derived
from hematologic cancers including B-cell lymphoma due to the
loss of BCR-mediated signaling events, their main source of pro-
survival signals4–8. Together with the striking efficacy of PCLX-
001 in pre-clinical models of B-cell lymphoma in vivo, these
findings support the ongoing development and potential clinical
trials of PCLX-001 and related NMT inhibitors as therapies for B
cell lymphoma and possibly other cancers.
Methods
Antibodies and materials. Rabbit anti-PARP-1 (1:5000, affinity purified poly-
clonal#EU2005, lot 1), anti-GAPDH (1:5000, affinity purified polyclonal, #EU1000,
lot 1), and anti-GFP (1:10,000, affinity purified, #EU1, lot B3-1) were from
laboratory stock and are available through Eusera (www.eusera.com). Our affinity
purified rabbit anti-GFP is also available as Ab6556 from Abcam (Cambridge,
MA). Rabbit monoclonal anti-Src (1:2000, clone 32G6, #2123, lot 5), Lyn (1:2000,
clone C13F9, #2796, lot 4), P-Lyn Y507 (1:5000, polyclonal, #2731, lot 5), Fyn
(1:2000, polyclonal, #4023, lot 3), Lck (1:2000, clone D88, #2984, lot 4), Hck
(1:2000, clone E1I7F, #14643, lot 1), c-Myc (1:10,000, clone D3N8F, #13987, lot 5),
ERK (1:2000, clone 4695, #9102, lot 27), P-ERK (1:5000, clone 3510, #9101, lot 30),
P-SFK (1:10,000, clone D49G4, #6943, lot 4), BTK (1:2000, clone D3H5, #8547, lot
13), P-BTK Y223 (1:5000, clone D9T6H, #87141, lot 1) SYK (1:2000, clone D3Z1E,
#13198, lot 5), P-SYK Y525/526 (1:5000, clone C87C1, lot 18), and anti-cleaved
caspase-3 (1:1000, clone 5A1E, #9664, lot 20) were purchased from Cell Signaling
Technologies. Rabbit monoclonal anti-BIP (1:2000, polyclonal, ADI-SPA-826) was
purchased from Enzo Life Sciences. Rabbit anti-Mcl-1 (1:2000, clone Y37, #32087,
lot GR119342-5), NFκB (1:2000, clone E379, #32536, lot GR3199609-2), P-Lyn
Y396 (1:5000, polyclonal, #226778, lot GR3195652-5) were purchased from Abcam
(Cambridge, MA). Mouse monoclonal anti-p-Tyr (1:10,000, PY99, sc-7020, lot
I2118) antibody was purchased from Santa Cruz Biotechnology. Mouse anti human
HGAL was purchased at eBioscience (1:10,000, clone 1H1-A7, #14-9758-82, lot
E24839-101). Rabbit polyclonal anti-ARF-1 antibody (1:2000, polyclonal, #PA1-
127, lot TK 279638) was purchased from ThermoFisher Scientific. Enhanced
chemiluminescence (ECL) Prime Western blotting detection kits were purchased
from GE Healthcare. Clarity ECL western blotting substrate was from Bio-Rad.
Goat anti-human IgM (μ chain) (70-8028-M002, lot S728028002001) was pur-
chased from Tonbo biosciences. Goat F(ab’)2 anti-human IgM was purchased from
BioRad (STAR146, lot 152684). Rabbit Anti-human Src antibody from Sigma-
Aldrich (polyclonal, Ab-529, lot 871521168) was used for immunoprecipitation.
Doxorubicin hydrochloride was from Pfizer. Dasatinib and ibrutinib were from
ApexBio Technology. PCLX-001 was identified as DDD86481 by Drs. David Gray
and Paul Wyatt (University of Dundee, Scotland, UK)38,69. All chemicals were of
the highest purity available and purchased from Sigma-Aldrich, unless indicated
otherwise.
Cell culture. IM9, Ramos, SU-DHL-10, and COS-7 were purchased from ATCC.
BL2, DOHH2, WSU-DLCL2, and BJAB were purchased from DSMZ (Germany).
Ramos and BL2 were kind gifts of Drs. Jim Stone and Robert Ingham of University
of Alberta. VDS isolation was described in Tosato et al.47. VDS, BJAB, and SU-
DHL-10 were kind gifts of Dr. Michael Gold of the University of British Columbia.
HUVEC cells (pooled from up to four umbilical cords) were purchased from
PromoCell. All cell lines identity was confirmed by STR profiling at The Genetic
Analysis Facility, The Centre for Applied Genomics, The Hospital for Sick Chil-
dren, Peter Gilgan Centre for Research and Learning, 686 Bay St., Toronto, ON,
Canada M5G 0A4 (www.tcag.ca). Cell lines were tested regularly for mycoplasma
contamination using MycoAlert Plus Mycoplasma Detection Kit (Lonza, ME,
USA). All cell lines tested negative for mycoplasma contamination. All cell lines
were maintained in RPMI or DMEM medium supplemented with 5–10% fetal
bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin, 1 mM sodium pyr-
uvate, and 2 mM L-glutamine. HUVEC cells (pooled from up to four umbilical
cords) were purchased from PromoCell and cultured in Endothelial cell growth
media with Insulin-like Growth Factor (Long R3 IGF) and Vascular Endothelial
Growth Factor and maintained at passages lower than seven. All cell lines were
maintained at 37 °C and 5% CO2 in a humidified incubator and routinely checked
for the presence of contaminating mycoplasma. Please see Supplementary Table 3
for cell line names, types and histology. For transfections, adherent cells COS-7
cells were transfected using X-tremeGENE9 DNA (Roche) transfection reagent
according to manufacturer’s instructions. For BCR activation experiments, cells
were incubated with 25 μg/ml of Goat F(ab’)2 anti-human IgM (or anti-human IgM
(μ chain) showing identical BCR activation properties) for 2 min and the activation
was stopped by the addition of 1 mM vanadate (Bio Basic Inc) solution in PBS.
Lysis of cells. Cells were harvested, washed in cold PBS, and lysed in 0.1% SDS-
RIPA buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% Igepal CA-630, 0.5%
sodium deoxycholate, 2 mM MgCl2, 2 mM EDTA with 1× complete protease
inhibitor; (Roche Diagnostics) by rocking for 15 min at 4 °C. The lysates were
centrifuged at 16,000 g for 10 min at 4 °C, and the post-nuclear supernatant was
collected.
Immunoblotting, immunoprecipitation, and metabolic labeling of cells with
alkyne-myristate. Protein concentrations were determined by BCA assay (Thermo
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Scientific) according to manufacturer’s instructions. Samples were prepared for
electrophoresis by the addition of 5× loading buffer and boiled for 5 min. If not
stated otherwise, 30 μg of total protein per lane is loaded on a 12.5% acrylamide
gels. After electrophoresis, gels are transferred onto 0.2 μM nitrocellulose mem-
brane (Bio-Rad) thereafter probed with antibodies as described in materials section.
Peroxidase activity is revealed following the procedure provided for the ECL Prime
Western Blotting Detection Reagent (GE Healthcare, PA, USA).
Immunoprecipitation was performed as previously described in Yap et al.47.
Briefly, cells are washed with cold PBS, harvested, and lysed with cold EDTA-free
RIPA buffer (0.1% SDS, 50 mM HEPES, pH 7.4, 150 mM NaCl, 1% Igepal CA-630,
0.5% sodium deoxycholate, 2 mM MgCl2, EDTA-free complete protease inhibitor
(Roche)) by rocking for 15 min at 4 °C. Cell lysates are centrifuged at 16,000 g for
10min at 4 °C and the post-nuclear supernatants are collected. EGFP fusion proteins
or endogenous c-Src non-receptor tyrosine kinase (Src) were immunoprecipitated
from approximately 1 mg of protein lysates with affinity purified goat anti-GFP
(www.eusera.com) or rabbit anti-Src antibody (Sigma, Ab-529, lot 871521168) by
rocking overnight at 4 °C. Pure proteome protein G magnetic beads (Millipore) were
incubated with immunoprecipitated proteins for 2 h and extensively washed with
0.1% SDS-RIPA, re-suspended in 1% SDS in 50mM HEPES, pH 7.4 and heated for
15min at 80 °C. The supernatants containing the immunoprecipitated proteins were
collected for Western blot analysis or click chemistry.
IM9, BL2, and COS-7 cells were treated with PCLX-001 for 1 h and cells were
then labeled with 25 μM ω-alkynyl myristic acid 30 min before harvesting at each
time point. Protein from the resulting cell lysates were reacted with 100 μM azido-
biotin using click chemistry and processed as described in Yap et al.47 and
Perinpanayagam et al.33.
Viability of cells treated with PCLX-001, dasatinib, and ibrutinib. IM9, VDS,
BL2, Ramos, BJAB, DOHH2, WSU-DLCL2, and SU-DHL-10 cells (1 × 105 cells)
were grown in six-well plates in 4 ml media/well and incubated with increasing
concentrations of PCLX-001, dasatinib, and ibrutinib for up to 96 h. Viability of
cells treated with PCLX-001 was measured by CellTiter-Blue Cell Viability Assay
(Promega) or with calcein AM staining (Life Technologies) according to the
manufacturer’s instructions on a Cytation 5 plate reader (Biotek, Winooski, VT).
Calcein assay consists of measuring the cell viability ratio (live cells/total cells and
expressed as % viability). Cells were stained with the Nuclear-ID Blue/Red cell
viability reagent (GFP-certified, Enzo Life Sciences) to identify total cells, and dead
cells while live cells were stained with Calcein AM (Life Technologies) according to
manufacturer’s instructions. Cell count was performed using a Cytation 5 Cell
Imaging Multi-Mode Reader (Biotek Instruments, Inc.) and analyzed by Biotek
Gen5 Data Analysis software (version 2.09).
Cell viability was also measured using the Horizon (St. Louis, MO) platform.
Cells were seeded in growth media in black 384-well tissue culture treated plates at
500 cells per well. Cells are equilibrated in assay plates via centrifugation and
placed in incubators at 37 °C for 24h before treatment. At the time of treatment, a
set of assay plates (which do not receive treatment) are collected and ATP levels are
measured by adding ATPLite© (PerkinElmer, Waltham, MA). These Tzero (T0)
plates are read using ultra-sensitive luminescence on Envision plate readers. Assay
plates are incubated with compound for 96 h (except where noted in Analyzer) and
are then analyzed using ATPLite©. All data points are collected via automated
processes and are subject to quality control and analyzed using Horizon’s Chalice
Analyzer proprietary software (1.5). Assay plates were accepted if they passed the
following quality control standards: relative raw values were consistent throughout
the entire experiment, Z-factor scores were greater than 0.6 and untreated/vehicle
controls behaved consistently on the plate. Horizon utilizes Growth Inhibition (GI)
as a measure of cell growth. The GI percentages are calculated by applying the
following test and equation:
If T < V0 : 100  1
T  V0
V0
 
;
If T ≥ V0 : 100  1
T  V0
V  V0
 
;
where T is the signal measure for a test article, V is the untreated/vehicle-treated
control measure, and V0 is the untreated/vehicle control measure at time zero (also
colloquially referred as T0 plates). This formula is derived from the Growth
Inhibition calculation used in the National Cancer Institute’s NCI-60 high
throughput screen. 100% GI therefore represents complete growth inhibition
(cytostasis) while 200% GI represents complete cell death.
Cell viability was also measured using the Oncolines (Netherlands Translational
Research Center B.V.) platform. Cells were diluted in the corresponding ATCC
recommended medium and dispensed in a 384-well plate, depending on the cell
line used, at a density of 200–6400 cells per well in 45 µl medium. For each used cell
line the optimal cell density is used. The margins of the plate were filled with
phosphate-buffered saline. Plated cells were incubated in a humidified atmosphere
of 5% CO2 at 37 °C. After 24 h, 5 µL of compound dilution was added and plates
were further incubated. At t = end, 24 µL of ATPlite 1Step™ (PerkinElmer) solution
was added to each well, and subsequently shaken for 2 min. After 10 min of
incubation in the dark, the luminescence was recorded on an Envision multimode
reader (PerkinElmer).
Finally, 3rd breadth of PCLX-001 efficiency screen (Supplementary Fig. 2) was
performed using the ChemPartner platform (Shanghai, China). One hundred and
thirty one cell lines were seeded in 96-well plate, black wall, tissue culture treated
(from Corning, Cat.3904) and cultured following ATCC formulation. Cell viability
after 72 and 144 h was measured using Cell Titer Blue Viability Assay (from
Promega, Cat. G8081, Lot. No. 0000190181) and fluorescence at 560/590 nm was
recorded with Enspire (PerkinElmer). EC50 was calculated using XLfit
software (5.5).
Cell proliferation assay. Proliferation of cells was measured by imaging and
counting after digital phase contrast picture transformation for better accuracy. 2 ×
105 cells were cultured in six-well plates in 4 ml of culture media and incubated
with increasing concentration of PCLX-001. After homogenization, 50 μl of culture
was transferred into a high binding clear glass bottom ½ area 96 well plate (Greiner
bio-one). Total well area was imaged in bright field (12 stitched pictures) using a
Cytation 5 Cell Imaging Multi-Mode Reader (Biotek Instruments, Inc.) and
transformed into a single digital phase contrast picture. Total cell counts were
performed daily for up to 4 days (Biotek Gen5 Data Analysis software 2.09).
Intracellular calcium measurements. Cytosolic free calcium concentration
measurements were performed in BL2 lymphoma cells incubated for 24 or 48 h
with 1 μM PCLX-001, dasatinib or ibrutinib using PTI fluorometer (Photon
Technology International) using adapted previously described protocol53. 10 × 106
cells are suspended in fresh media with 8 μM Fura-2 AM (Molecular Probes) and 1
mM CaCl2 for 30 min, washed and resuspended in media supplemented with
calcium for an additional 15 min. Cells are then washed and resuspended in warm
Krebs Ringer solution (10 mM HEPES pH 7.0, 140 mM NaCl, 4 mM KCl, 1 mM
MgCl2 and 10 mM glucose) and placed in a four-sided clear cuvette. Prior to
activation, the free cytoplasmic calcium was chelated with 0.5 mM EGTA for 1 min.
BCR receptor dependent calcium release is activated by the addition of 10 μg/ml
Goat F(ab′)2 anti Human IgM (BioRad). Following, Thapsigargin (300 nM) was
used to show BCR-independant and irreversible Ca2+ release from the endo-
plasmic reticulum. Ca2+ concentrations were calculated with the following
equation:
[Ca++] = Kd (R–Rmin)/(Rmax–R) with R = Fluorescence Intensity at 340 nm
divided by fluorescence intensity at 380 nm, Rmax = fluorescence measured
following Ionomycin (7.5 μM) and CaCl2 (12 mM) addition, Rmin = fluorescence
measured following EGTA (32mM), Tris (24 mM) and Triton X-100 (0.4%) and
Kd = 224 (at 37 °C for Fura-2 AM).
Results shown are representative of multiple replicates of the experiment (n = 6
for PCLX-001 incubation, n = 3 for Dasatinib and Ibrutinib).
Isolation of PBMC and lymphocytes and cell viability assay. Two healthy
human research volunteers were recruited for PBMC and lymphocytes isolation
from a 20ml blood collection (patient #1: male, 34 years old, no diagnosis, no
treatment; patient #2: male, 54 years old, no diagnosis, no treatment). Study
protocol was approved by the Health Research Ethics Board of Alberta Cancer
Committee (Study title: Evaluations of Fatty AcylTransferases (FATs) in fresh
blood and blood forming cells; HREBA.CC-17-0624).
Mononuclear cells were isolated from peripheral blood by density gradient
centrifugation using Ficoll-Paque (GE Healthcare, PA, USA). Lymphocytes were
isolated from whole blood samples using EasySepTM lymphocyte isolation kit
(Stemcell Technologies, Vancouver, BC, Canada) as per manufacturer’s
instructions. PBMC and lymphocytes were cultured in RPMI medium with 10%
FBS, 100 U/ml penicillin, 0.1 mg/ml streptomycin. Cells were plated at a
concentration of 2 × 106 cells/ml. After incubation with 0.001–10 µM PCLX-001
for 96 h, cell viability was measured by using CellTiter-FluorTM viability assay
(Promega, Madison, WI, USA).
Immunohistochemistry. COS-7 cells were cultured plated on Poly-d-Lysine-
coated 35-mm glass-bottom dishes (MatTek Corporation, Ashland, MA, USA) and
transiently transfected with the indicated fluorescently tagged proteins using X-
tremeGENE9 DNA (Roche) as recommended by the suppliers. Images were
acquired using a Zeiss Observer Z1 microscope and Axiovision software (Axiovi-
sion, version 4.8). B-cell lymphomas were fixed in formalin, embedded in paraffin,
cut into 5 mm sections with a microtome, mounted on Superfrost Plus slides
(Fisher Scientific), deparaffinized with xylene (three times for 10 min each),
dehydrated in a graded series of ethanol (100, 80 and 50%), and washed in running
cold water for 10 min.
For antigen retrieval, slides were loaded in a slide holder and placed in a
Nordicware microwave pressure cooker. 800 ml 10 mM citrate buffer pH 6.0 was
added, and the pressure cooker was tightly closed and microwaved on high for
20 min. The slides were washed in cold running water for 10 min, soaked in 3%
H2O2 in methanol for 10 min, and washed with warm running water for 10 min
and with PBS for 3 min. Excess PBS was removed and a hydrophobic circle was
drawn around the sample with a PAP pen (Sigma-Aldrich, St. Louis, MO). Anti-
cleaved caspase 3 or anti-Ki-67 were diluted with Dako antibody diluent buffer
(1:50, ∼400 μl per slide), and incubated in a humidity chamber overnight at 4 °C.
Slides were washed in PBS twice for 5 min each and ∼4 drops of EnVision
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+System-HRP labeled polymer (anti-rabbit) (Dako, Agilent Technologies, Santa
Clara, CA) was added to each slide and incubated at room temperature for 30 min.
Slides were washed again in PBS twice for 5 min each, and 4 drops of liquid
diaminobenzidine+ substrate chromogen (prepared according to manufacturer’s
instructions; Dako, Agilent Technologies) was added. The slides were developed for
5 min and rinsed under running cold water for 10 min. The slides were then soaked
in 1% CuSO4 for 5 min, rinsed briefly with running cold water, counterstained with
haematoxylin for 60 s, and rinsed with running cold water. Next, slides were dipped
in lithium carbonate three times, rinsed, and dehydrated in a graded series of
ethanol. Coverslips were added, and the slides were examined with a Nikon Eclipse
80i microscope and photographed with a QImaging camera.
Ethics approval. We have complied with all relevant ethical regulations for
human, animal testing and research. All relevant experiments in this study have
received the appropriate ethical approval. The name of board and/or institution
that approved the study protocol are described below.
Charles River Discovery Services North Carolina (CR Discovery Services)
specifically complies with the recommendations of the Guide for Care and Use of
Laboratory Animals with respect to restraint, husbandry, surgical procedures, feed
and fluid regulation, and veterinary care. The animal care and use program at CR
Discovery Services is accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International, which assures compliance
with accepted standards for the care and use of laboratory animals.
In Vivo Services at The Jackson Laboratory—Sacramento facility, an OLAW-
assured and AAALAC-accredited organization conducted the DOHH2 mouse
xenograft study. It was performed according to an Institutional Animal Care and
Use Committee (IACUC)-approved protocol and in compliance with the Guide for
the Care and Use of Laboratory Animals (National Research Council, 2011).
For the study using DLBCL lymphocytes, all procedures were approved and
carried out in accordance with the guiding ethical principles of the Institutional
Review Board of the Singapore General Hospital. Written informed consent was
obtained for use of these samples for the specific research purpose only. The
experimental protocol (#130812) was approved by the IACUC of the Biological
Resource Center (BRC), A*STAR. All procedures involving human samples were
approved by and performed in accordance with the ethics principles of the Sing
Health Centralized Institutional Review Board. Written informed consent was
obtained for use of these samples for the specific research purpose only. Our
patients have given consent to use their tissue samples and associated
demographical and clinical data in a de-identified format.
Xenograft studies in mice. DOHH2 xenograft study at Charles River’s facility:
Female severe combined immunodeficient mice (Fox Chase SCID®, C.B-17/Icr-
Prkdcscid/IcrIcoCrl, Charles River) were 9 weeks old on Day 1 of the study and
had a BW range of 17.8–22.9 g. The animals were fed ad libitum water (reverse
osmosis, 1 ppm Cl) and NIH 31 Modified and Irradiated Lab Diet® consisting of
18.0% crude protein, 5.0% crude fat, and 5.0% crude fiber. On Day 1 of the study,
animals were given a rehydration solution ad libitum in an effort to reduce
dehydration during the dosing phase of the study. The rehydration solution con-
sisted of 0.45% NaCl, 2.5% glucose, and 0.075% KCl in sterile water. The mice were
housed on irradiated Enrich-o’cobs™ bedding in static microisolators on a 12-h
light cycle at 20–22 °C (68–72 °F) and 40–60% humidity.
BL2 xenograft study at Jackson Laboratory: One hundred and five 6-week-old
female NOD.CB17-Prkdc scid/J (NOD scid, Stock #001303) mice were transferred
to the in vivo research laboratory in Sacramento, CA. The mice were ear notched
for identification and housed in individually and positively ventilated polysulfone
cages with HEPA filtered air at a density of 5 mice per cage. Initially cages were
changed every two weeks. The animal room was lighted entirely with artificial
fluorescent lighting, with a controlled 12 h light/dark cycle (6 a.m. to 6 p.m. light).
The normal temperature and relative humidity ranges in the animal rooms were
20–26 °C and 30–70%, respectively. The animal rooms were set to have up to 15 air
exchanges per hour. Filtered tap water, acidified to a pH of 2.5–3.0, and standard
lab chow were provided ad libitum.
BL2 or DOHH-2 cells (1 × 107) and a cell suspension containing neoplastic
DLBCL lymphocytes isolated from the pleural fluid of consented patient DLBCL3
were subcutaneously injected into the flank of immuno-compromised, female,
NODscid mice at the Jackson Laboratory’s, Charles River’s, and Singapore General
Hospital’s facilities, respectively. After tumors formed, mice were divided into
groups of approximately ten animals and given subcutaneous injections of vehicle
daily, PCLX-001 daily at 10–60 mg/kg, or doxorubicin weekly at 3 mg/kg70, as
indicated in each figure. The dose volume was 10 mL/kg. At the end of the 2- to 3-
week dosing period, mice were euthanized and three/group were necropsied. Mice
that died or were euthanized early for humane reasons also were necropsied. In life,
mice were monitored regularly and weighed daily, and tumors were measured with
digital Vernier calipers (Mitutoyo) every other day. Tumor volume was calculated
as length (mm) × width (mm)2/2; length and width were the longest and shortest
diameters, respectively. At euthanasia, at the end of the dosing period blood
samples were taken for hematology analyses and clinical chemistry analyses that
included AST and CK activities and bilirubin and creatinine concentrations (plus
ALT activity and BUN concentration in the Jackson Laboratory study). At
necropsy, samples of femur, both kidneys, liver, small intestine, and injection site
were collected and fixed. These were subsequently processed and examined by light
microscopy for histopathologic findings. Also at necropsy, the tumors were
removed and divided in two. One piece was fixed in 10% neutral buffered formalin
for 24 h at room temperature and embedded in paraffin; the other was snap frozen
for RNA and protein analysis. TGI for all xenograft experiments was calculated
following the formula:
TGI %ð Þ ¼ Vcontrol  Vtreatedð Þ= Vcontrol  Vinitialð Þ  100:
Patient derived xenograft mouse studies
(i) Patient sample. Patient DLBCL3 had been treated for Stage I diffuse large B-cell
lymphoma with cyclophosphamide, doxorubicin, vincristine, and prednisolone
(CHOP), which resulted in complete remission (Supplementary Table 2). Patient
DLBCL3 then presented to Singapore General Hospital 10 years subsequently with
recurrent disease in the bone marrow and leptomeninges and pleural effusions. The
patient received two courses of rituximab, ifosfamide, carboplatin, and etoposide
and intrathecal methotrexate/cytarabine, followed by four courses of dex-
amethasone, cytarabine, and cisplatin and intrathecal methotrexate. The patient’s
tissue was harvested for PDX propagation at this time. The disease continued to
progress, and the patient died a year later.
(ii) Pathology. Cytological examination of the pleural fluid showed discohesive
lymphomatous population featuring large cells with vesicular chromatin and
conspicuous nucleoli. Neoplastic cells expressed pan-B markers (PAX5, CD20,
CD22, CD79a), with aberrant expression of CD5, strong expression of bcl2, and a
high proliferation fraction (70–80%). Neoplastic lymphocytes had a nongerminal
center phenotype (negative for CD10 and positive for bcl6, MUM1, FOXP1) but
staining for c-Myc was low (20%). Interphase fluorescence in situ hybridization
showed gains of BCL2 and rearrangements of BCL6 and IGH; normal patterns were
seen for C-MYC. RNA in situ hybridization showed lack of NMT2 expression.
(iii) Xenograft construction and treatment. The pleural fluid was collected in cold
sterile 20% RPMI 1640 medium and neoplastic cells were isolated with Ficoll-
Paque Plus (GE Healthcare) and re-suspended in RPMI 160 medium (Life Tech-
nologies) with 20% fetal bovine serum (Life Technologies, Carlsbad, CA). A
representative part of the tumor sample was fixed in 10% neutral buffered formalin;
the other part was used for xenotransplantation. The cell suspension was injected
subcutaneously in the flank of 4–6-week-old NODscid mice. When the tumors
reached a maximum of 1000 mm3, the mice were sacrificed, tumors were harvested,
and a necropsy was performed. Xenograft tumors were immediately frozen, fixed in
formalin, and stored in 90% fetal bovine serum, and 10% dimethyl sulfoxide or
placed in RPMI 1640 medium. This process was repeated to produce subsequent
generations of patient-derived xenograft models (P2, P3, P4, …). To evaluate the
maintenance of the morphology and main characteristics of the tumor of origin,
formalin-fixed, paraffin-embedded tissue sections from patient tumor samples and
xenografts of all established patient-derived xenograft models were stained with
haematoxylin and eosin. These sections were also immunostained to measure the
expression of various markers. A clinical pathologist reviewed all the slides. For the
current study, tumor fragments (∼50 mg, P4) were implanted subcutaneously in
the flank of 4–6-week-old female NODscid mice and allowed to grow to 200–300
mm3. The mice were then randomized into groups (n= 8 per group) and injected
subcutaneously with vehicle (10 ml/kg); PCLX-001, 20 mg/kg daily for 21 days; or
PCLX-001, 50 mg/kg daily for 18 days, with a 3-day break after 9 days. Tumor
measurements and growth inhibition calculations were performed as
described above.
For the DLBCL3 PDX study, NODscid mice were purchased from InVivos,
Singapore and fed with standard laboratory diet and distilled water ad libitum. The
animals were kept on a 12 h light/dark cycle at 22 ± 2 °C in BRC, A*STAR and
maintained in accordance with the institutional guidelines.
NMT activity assay. NMT activity assay was described in Perinpanayagam et al.33.
Briefly, cells were lysed and sonicated (10 s) in sucrose buffer (50 mM NaH2PO4,
pH 7.4, and 0.25 M sucrose). Tumor samples were cut into small pieces, extracted
by glass Dounce homogenization (12 full strokes) in sucrose buffer, and sonicated
(10 s). The protein lysates were incubated with 0.1 mM of myristoylatable or non-
myristoylatable decapeptide corresponding to the N-terminal sequence of p60-Src
and 12 pM of [3H]-myristoyl-CoA (PerkinElmer, Waltham, MA) in NMT assay
buffer (0.26 M Tris-HCl pH 7.4, 3.25 mM EGTA, 2.92 mM EDTA and 29.25 mM
2-mercaptoethanol, 1% Triton X-100) in 25 μl reactions and incubated for 15 min
at 30 °C. The reaction was terminated by spotting 15 μl of the reaction mixture
onto a P81 phosphocellulose paper disc (Whatman, Maidstone, UK), washed and
processed for scintillation counting.
Statistical methods. Data were analyzed using Prism 8 software (GraphPad,
version 8.4.1) and generally expressed as mean ± s.e.m. Statistical significance was
determined using Student t test or one-way ANOVA when applicable. Analysis of
the significance of drug treatments on tumor volume was assessed by two-way
ANOVA. P values higher than 0.05 were not considered statistically significant.
***P ≤ 0.001, **P ≤ 0.01, and *P ≤ 0.05.
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Statistical analysis of NMT1 and NMT2 expression: NMT1 and NMT2 mRNA
expression data were extracted on March 26th 2020 from the Broad Institute CCLE
database54 (https://portals.broadinstitute.org/ccle) and contained the mRNA
expression data for 1269 cancer cell lines. The RNAseq TPM gene expression data
(Expression Public 20Q1) were analyzed for protein coding genes using RSEM and
are presented as Log2 transformed values using a pseudo-count of one
(Supplementary Fig. 15).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Source data are provided with this paper. The data that support the findings of this study
are available from the corresponding author upon reasonable request. Source data are
provided with this paper.
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